BioCentury
ARTICLE | Company News

BioCurate names Begley CEO

May 1, 2017 11:32 PM UTC

BioCurate Pty Ltd., an independent A$80 million ($60 million) non-profit joint venture of Monash University and the University of Melbourne, named C. Glenn Begley as its first CEO. BioCurate was launched last June to promote commercialization of research produced by Melbourne academics, and receives additional funding from the state government of Victoria (see BioCentury Innovations, June 30, 2016).

Begley was most recently CSO of Akriveia Therapeutics LLC (Thousand Oaks, Calif.), and was previously CSO at TetraLogic Pharmaceuticals Corp. and vice president and global head of hematology and oncology research at Amgen Inc. (NASDAQ:AMGN). He has been an outspoken advocate for reforming standards of scientific reproducibility...